Addex Therapeutics (ADXN) Q1 2026 earnings review
Survival Mode: The Cash Cliff is Imminent
Addex Therapeutics is running out of time. The company ended Q1 2026 with a perilously low CHF 0.9 million in cash, providing a runway only through July 2026. While management points to external progress—namely, spin-out Neurosterix advancing to Phase 1 and partner Indivior completing IND-enabling studies—the internal engine has completely stalled. Q1 outsourced R&D spend collapsed to an insignificant CHF 9,000, contradicting the narrative that Addex is actively advancing its pipeline. The company is surviving week-to-week via highly dilutive equity sales at penny-stock prices (~CHF 0.05). Addex is effectively operating as a passive holding company for its 20% Neurosterix stake and Indivior milestone rights, desperately awaiting an external financial lifeline.
🐂 Bull Case
The 20%-owned spin-out Neurosterix is fully funded and expects Phase 1 data for its M4 PAM (schizophrenia) in July 2026. Positive data could provide a critical value inflection or monetization opportunity.
Partner Indivior has successfully completed IND-enabling studies for its GABAB PAM in Substance Use Disorder. If Indivior advances into clinical trials, Addex is eligible for a portion of the $330M in milestone payments.
🐻 Bear Case
With CHF 0.9M in the bank and a runway ending in July 2026, the going concern risk is critical. Any delay in external funding or partner milestones will be fatal or force devastating dilution.
With only CHF 36k total spent on R&D in Q1, the company's unpartnered assets (like the chronic cough candidate) are entirely stalled, destroying near-term organic value creation.
⚖️ Verdict: 🔴🔴
Very Bearish. The company is on the brink of insolvency with just four months of runway remaining from the reporting date. Operations have been slashed to the bone, and the company is entirely reliant on the clinical success and financial timelines of external partners over which it has zero control.
Key Themes
The 'Advancing Pipeline' Illusion
Management stated in the press release that they 'continued advancing' the GABAB PAM chronic cough candidate through preclinical development. The data directly contradicts this narrative. Q1 2026 outsourced R&D spend for the GABAB PAM was CHF 0 (down from CHF 30k YoY). Total outsourced R&D for the entire company was a mere CHF 9,000. You cannot run a clinical-stage biopharma on this budget. The internal pipeline is effectively frozen until new financing is secured.
Extreme Dilution at Micro-Cap Valuations
To keep the lights on, Addex is leaning heavily on At-The-Market (ATM) and liquidity agreements. In Q1 2026, the company sold 1.44 million shares to raise a negligible CHF 73k. Post-close (April to June), they sold another 6.45 million shares to raise CHF 288k. Selling stock at roughly CHF 0.04 to 0.05 per share is highly destructive to existing shareholders and indicates a lack of institutional financing options.
Transformation into a Passive Holding Company
With internal R&D halted, Addex operates primarily as a holding shell. Its core value rests entirely on a 20% equity stake in Neurosterix (currently carrying a balance sheet value of CHF 2.6M) and milestone rights from Indivior and Sinntaxis. G&A expenses (CHF 451k) are now more than 12x higher than R&D expenses (CHF 36k), reflecting the cost of maintaining a public listing rather than developing drugs.
Neurosterix M4 PAM Catalyst
The spin-out Neurosterix remains Addex's brightest short-term catalyst. It is well-funded ($65M raised) and on track to complete Phase 1 trials for NTX-253, an M4 Positive Allosteric Modulator for schizophrenia, in July 2026. Given the recent M&A boom in neuropsychiatry, a successful Phase 1 readout could significantly revalue Addex's 20% stake.
Indivior Partnership Advances
Indivior successfully completed IND-enabling studies for the jointly discovered GABAB PAM targeting Substance Use Disorder. This is a critical step. Addex is eligible for up to $330M in milestone payments plus royalties. If Indivior doses the first patient in clinical trials, it will trigger an upfront milestone that could rescue Addex's balance sheet.
Differentiated GABAB Mechanism for Chronic Cough
Despite the lack of current funding, the GABAB PAM chronic cough asset remains highly viable technology. Management correctly points out that peripherally-acting P2X3 inhibitors fail in up to 50% of patients and suffer from severe taste disturbances. Addex's centrally-acting approach has shown a >60x safety margin in preclinical models. It is a prime out-licensing candidate if management can find a buyer.
Hostile Macro Financing Environment
The company relies heavily on broader macroeconomic recovery to execute its strategy. Management explicitly noted that portfolio companies like Stalicla depend on a 'warming up of the market' for potential IPOs. Geopolitical risks and elevated interest rates continue to choke off capital for pre-clinical and early-clinical CNS assets, directly threatening Addex's ability to refinance before July.
Other KPIs
Accelerating. Up from CHF -0.85 million in Q1 2025. This non-cash charge represents Addex's 20% absorption of Neurosterix's Phase 1 clinical trial expenses. While it increases the headline net loss, it is actually a reflection of healthy, funded clinical progress happening at the partner level.
Decelerating. Down from CHF 521,000 in Q1 2025. The reduction is primarily driven by lower professional and legal fees. However, at ~CHF 1.8M annualized, G&A burn alone is twice the company's remaining cash balance, highlighting the unsustainability of the current structure.
Guidance
Decelerating. The official guidance from management states that the current cash of CHF 935k is sufficient only through July 2026. This formally triggers a 'going concern' warning from the auditors. The runway has continually compressed without a substantial capital raise.
Key Questions
Bridging the July Cash Cliff
With the cash runway ending next month (July 2026), what binding commitments or bridge financing facilities are currently in place to avoid insolvency if partner milestones are delayed?
Monetizing the Neurosterix Stake
If Neurosterix produces positive Phase 1 data for NTX-253 this summer, are there structural mechanisms in place that would allow Addex to borrow against, or sell a portion of, its 20% equity stake to fund its own operations?
Definition of Pipeline 'Advancement'
With outsourced R&D spend dropping to just CHF 9k for the quarter, how are you practically 'advancing' the GABAB PAM chronic cough program, and what specific IND-enabling steps remain?
Indivior Milestone Timing
Now that Indivior has completed IND-enabling studies for the SUD candidate, what is their stated timeline for filing the IND and initiating Phase 1, and what is the exact dollar amount of the milestone tied to that event?